Blood pressure control and prevention of stroke

References

• Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 60(3), 1347–1360 (2002).
   Google Scholar
• Spencer C, Lip GYH. Hypertension: (1) epidemiology and risks. Pharm. J. 7059(263), 280–283 (1992).
   Google Scholar
• Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345(18), 1291–1297 (2001).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomized double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 352(9137), 1347–1351 (1998).
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation study investigators. Patients at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III study. JAMA 279(16), 1273–1277 (1998).
   PubMed Web of Science ®Google Scholar
• Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Co-operative Research Group. JAMA 276(23), 1886–1892 (1996).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and co-ordinators for the ALLHAT Colloborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304(6824), 405–412 (1992).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359(9311), 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Kato J, Eto T. Diuretics in the LIFE study. Lancet 364(9432), 413–414 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE. Author’s reply. Lancet 364(9432), 413–414 (2004).
   PubMedGoogle Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358(9287), 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Cardiovascular events in hypertension trials of angiotensin converting-enzyme inhibitors. J. Clin. Hypertens. 7(8 Suppl. 2), 2–4 (2005).
   Google Scholar
• Blood Pressure Lowering Treatment Trialists Collaborative. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 362(9395), 1527–1545 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Wing LM, Reid CM, Ryan P et al.; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348(7), 583–592 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354(9192), 1751–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353(9153), 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lindholm L et al. The Captopril Prevention Project (CAPPP) in hypertension-baseline data and current status. Blood Press. 6(6), 365–367 (1997).
   PubMedGoogle Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. BMJ 317(7160), 713–720 (1998).
   PubMed Web of Science ®Google Scholar
• Chatellier G, Mann JFE, Passa P, Menard J:; DIABHYCAR study investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with Type 2 diabetes and raised excretion of urinary albumin: randomized, double-blind placebo-controlled trial. BMJ 328, 495–509 (2004).
   PubMed Web of Science ®Google Scholar
• Fournier A, Achard JM, Mazouz H et al. Could angiotensin II Type I receptor antagonists have a superior beneficial effect than that of angiotensin II converting enzyme inhibitors with respect to the risk of cerebrovascular accident? Arch. Mal. Coeur Vaiss. 92(8), 997–1000 (1999).
   PubMedGoogle Scholar
• Fournier A, Ghitu A, Darabont R et al. Duality of angiotensin II receptors and risk for stroke and cancer: what is the connection? Presse Med. 28(17), 918–922 (1999).
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D et al.; Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II Type I-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol. 44(6), 1175–1180 (2004).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al.; MOSES Study Group. MOrbidity and mortality after Stroke–Eprosartan compared with nitrendipine for Secondary Prevention. Stroke 36(6), 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363(9426), 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al.; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 34(7), 1699–1703 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am. J. Cardiol. 89(2A), A18–A25 (2002).
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Unger T. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in combination with Ramipril Global End point Trial programme. Expert Opin Pharmacother. 5(5), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Weber MA. Managing the patient at risk for a second stroke. J. Hypertens. 1(Suppl. 23), S41–S47 (2005).
   Google Scholar
• Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274(8), 620–625 (1995).
   PubMed Web of Science ®Google Scholar
• Black HR. Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials. Clin. Cornerstone 6(4), 53–66 (2004).
   PubMedGoogle Scholar
• Black HR, Elliott WJ, Grandits G et al.; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End points (CONVINCE) trial. JAMA 289(16), 2073–2082 (2003).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.; INVEST Investigators. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290(21), 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In:Textbook of Hypertension. Swales JD (Ed.). Blackwell Scientific Publishing, London, UK, 1156–1164 (1994).
   Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366(9496), 1545–1553 (2005).
   PubMed Web of Science ®Google Scholar
• Beevers DG. The end of β blockers for uncomplicated hypertension? Lancet 366(9496), 1510–1512 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Davis BR, Cutler JA, Furberg CD et al.; ALLHAT Collaborative Research Group. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann. Intern. Med. 137(5 Pt 1), 313–320 (2002).
   PubMed Web of Science ®Google Scholar
• Martin U, Hill C, O’ Mahony D. Use of moxonidine in elderly patients with resistant hypertension. J. Clin. Pharm. Ther. 30(5), 433–437 (2005).
   PubMed Web of Science ®Google Scholar
• Messerli F. Moxonidine: a new and versatile antihypertensive. J. Cardiovasc. Pharmacol. 35(7 Suppl. 4), S53–S56 (2005).
   Google Scholar
• van Zwieten PA. Centrally acting imidazoline II-receptor agonists: do they have a place in the management of hypertension? Am. J. Cardiovasc. Drugs 1(5), 321–326 (2001).
   PubMedGoogle Scholar
• Abellan J, Leal M, Hernandez-Menarguez F et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int. 93(Suppl.), S20–S24 (2005).
   Google Scholar
• Jacob S, Klimm HJ, Rett K, Helsberg K, Haring HU, Godicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 112(6), 315–322 (2004).
   PubMed Web of Science ®Google Scholar
• Lip GYH. Hypertension and the prothrombotic state. J. Hum. Hypertens. 14, 687–690 (2000).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Blann AD, Beevers DG. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. J. Hypertens. 17, 1203–1207 (1999).
   PubMed Web of Science ®Google Scholar
• Nadar S, Lip GYH. Hypertension and the prothrombotic state. J. Am. Coll. Cardiol.. 41, 1847 (2003).
   PubMedGoogle Scholar